FTC requires Hikma to let go of steroid drug as part of $375M acquisition of Custopharm
The Federal Trade Commission on Tuesday offered the biopharma industry a peek into how it may try to crack down on M&A.
As part of generic drug company Hikma’s proposed $375 million acquisition of generic injectable producer Custopharm, the commission is requiring that Hikma not acquire a generic corticosteroid drug known as triamcinolone acetonide, or TCA, and that Custopharm’s parent company retain and transfer the drug to a subsidiary, Long Grove Pharmaceuticals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
